Referências

1. Abreu, I.D., Nunes, P.V., Diniz, B.S., Forlenza, O.V., Combining functional scales and cognitive tests in screening for mild cognitive impairment at a university-based memory clinic in Brazil (2008) Rev Bras Psiquiatr, 30 (4), pp. 346-349
2. Aisen, P.S., Saumier, D., Briand, R., Laurin, J., Gervais, F., Tremblay, P., Garceau, D., A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease (2006) Neurology, 67, pp. 1757-1763
3. Aizenstein, H.J., Nebes, R.D., Saxton, J.A., Price, J., Mathis, C., Tsopelas, N.D., Ziolko, S.K., Houck, P.R., Frequent amyloid deposition without significant cognitive impairment among the elderly (2008) Arch Neurol, 65, pp. 1509-1517
4. Albert, M.S., DeKosky, S.T., Dickson, D., Dubois, B., Feldman, H.H., Fox, N.C., Gamst, A., Phelps, C.H., The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease (2011) Alzheimers Dement, 7 (3), pp. 270-279
5. Andreasen, N., Minthon, L., Davidsson, P., Vanmechelen, E., Vanderstichele, H., Winblad, B., Blennow, K., Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice (2001) Arch Neurol, 58, pp. 373-379
6. Apostolova, L.G., Dinov, I.D., Dutton, R.A., Hayashi, K.M., Toga, A.W., Cummings, J.L., Thompson, P.M., 3D comparison of hippocampal atrophy in amnestic mild cognitive impairment and Alzheimer's disease (2006) Brain, 129, pp. 2867-2873
7. Arai, H., Ishiguro, K., Ohno, H., Moriyama, M., Itoh, N., Okamura, N., Matsui, T., Kohno, H., CSF phosphorylated tau protein and mild cognitive impairment: a prospective study (2000) Exp Neurol, 166, pp. 201-203
8. Assini, A., Cammarata, S., Vitali, A., Colucci, M., Giliberto, L., Borghi, R., Inglese, M.L., Dagna-Bricarelli, F., Plasma levels of amyloid beta-protein 42 are increased in women with mild cognitive impairment (2004) Neurology, 63, pp. 828-831
9. Barbosa, I., Huguet, R., Mendonça, V., Sousa, L., Neves, F., Bauer, M., Teixeira, A., Increased plasma levels of soluble TNF receptor I in patients with bipolar disorder (2011) Eur Arch Psychiatry Clin Neurosci, 261 (2), pp. 139-143
10. Blacker, D., Lee, H., Muzikansky, A., Martin, E.C., Tanzi, R., McArdle, J.J., Moss, M., Albert, M., Neuropsychological measures in normal individuals that predict subsequent cognitive decline (2007) Arch Neurol, 64, pp. 862-871
11. Blasko, I., Jellinger, K., Kemmler, G., Krampla, W., Jungwirth, S., Wichart, I., Tragl, K.H., Fischer, P., Conversion from cognitive health to mild cognitive impairment and Alzheimer's disease: prediction by plasma amyloid beta 42, medial temporal lobe atrophy and homocysteine (2008) Neurobiol Aging, 29, pp. 1-11
12. Blass, J.P., Alzheimer's disease and Alzheimer's dementia: distinct but overlapping entities (2002) Neurobiol Aging, 23, pp. 1077-1084
13. Blennow, K., Hampel, H., CSF markers for incipient Alzheimer's disease (2003) Lancet Neurol, 2, pp. 605-613
14. Blennow, K., Cerebrospinal fluid protein biomarkers for Alzheimer's disease (2004) NeuroRx, 1, pp. 213-225
15. Blennow, K., Hampel, H., Weiner, M., Zetterberg, H., Cerebrospinal fluid and plasma biomarkers in Alzheimer disease (2010) Nat Rev Neurol, 6 (3), pp. 131-144
16. Bouwman, F.H., Schoonenboom, S.N., van der Flier, W.M., van Elk, E.J., Kok, A., Barkhof, F., Blankenstein, M.A., Scheltens, P., CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment (2007) Neurobiol Aging, 28, pp. 1070-1074
17. Brookmeyer, R., Gray, S., Kawas, C., Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset (1998) Am J Public Health, 88, pp. 1337-1342
18. Brookmeyer, R., Gray, S., Kawas, C., Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset (1998) Am J Public Health, 88, pp. 1337-1342
19. Brookmeyer, R., Johnson, E., Ziegler-Graham, K., Arrighi, H.M., Forecasting the global burden of Alzheimer's disease (2007) Alzheimers Dement, 3, pp. 186-191
20. Bruscoli, M., Lovestone, S., Is MCI really just early dementia? A systematic review of conversion studies (2004) Int Psychogeriatr, 16 (2), pp. 129-140
21. Brys, M., Pirraglia, E., Rich, K., Rolstad, S., Mosconi, L., Switalski, R., Glodzik-Sobanska, L., Mehta, P., Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment (2009) Neurobiol Aging, 30, pp. 682-690
22. Buchhave, P., Zetterberg, H., Blennow, K., Minthon, L., Janciauskiene, S., Hansson, O., Soluble TNF receptors are associated with Abeta metabolism and conversion to dementia in subjects with mild cognitive impairment (2008) Neurobiology of Aging, , [ahead of print]
23. Buerger, K., Ewers, M., Pirttil, T., Zinkowski, R., Alafuzoff, I., Teipel, S.J., DeBernardis, J., Soininen, H., CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease (2006) Brain, 129, pp. 3035-3041
24. Burton, C.L., Strauss, E., Bunce, D., Hunter, M.A., Hultsch, D.F., Functional abilities in older adults with mild cognitive impairment (2009) Gerontology, 55 (5), pp. 570-581
25. Busatto, G.F., Diniz, B.S., Zanetti, M.V., Voxel-based morphometry in Alzheimer's disease (2008) Expert Rev Neurother, 8, pp. 1691-1702
26. Busse, A., Hansel, A., Gühne, U., Angermeyer, M.C., Riedel-Heller, S.G., Mild cognitive impairment: long-term course of four clinical subtypes (2006) Neurology, 67, pp. 2176-2185
27. Caroli, A., Frisoni, G., the Alzheimer's Disease Neuroimaging I. The dynamics of Alzheimer's disease biomarkers in the Alzheimer's Disease Neuroimaging Initiative cohort (2010) Neurobiol Aging, 31 (8), pp. 1263-1274
28. Chetelat, G., Desgranges, B., de la Sayette, V., Viader, F., Eustache, F., Baron, J.C., Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer's disease? (2003) Neurology, 60 (8), pp. 1374-1377
29. Chetelat, G., Landeau, B., Eustache, F., Mezenge, F., Viader, F., de la Sayette, V., Desgranges, B., Baron, J.C., Using voxel-based morphometry to map the structural changes associated with rapid conversion in MCI: a longitudinal MRI study (2005) NeuroImage, 27, pp. 934-946
30. Chetelat, G., Eustache, F., Viader, F., De La Sayette, V., Pölerin, A., Mäzenge, F., Hannequin, D., Desgranges, B., FDG-PET measurement is more accurate than neuropsychological assessments to predict global cognitive deterioration in patients with mild cognitive impairment (2005) Neurocase, 11 (1), pp. 14-25
31. Citron, M., Alzheimer's disease: strategies for disease modification (2010) Nat Rev Drug Discov, 9, pp. 387-398
32. Clark, C., Xie, S., Chittams, J., Ewbank, D., Peskind, E., Galasko, D., Morris, J., Weitlauf, S.L., Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? (2003) Arch Neurol, 60, pp. 1696-1702
33. Cunningham, C., Campion, S., Lunnon, K., Murray, C.L., Woods, J.F., Deacon, R.M., Rawlins, J.N., Perry, V.H., Systemic inflammation induces acute behavioral and cognitive changes and accelerates neurodegenerative disease (2009) Biol Psychiatry, 65, pp. 304-312
34. Davatzikos, C., Xu, F., An, Y., Fan, Y., Resnick, S.M., Longitudinal progression of Alzheimer's-like patterns of atrophy in normal older adults: the SPARE-AD index (2009) Brain, 132, pp. 2026-2035
35. de Leon, M.J., Convit, A., Wolf, O.T., Tarshish, C.Y., DeSanti, S., Rusinek, H., Tsui, W., Fowler, J., Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET) (2001) Proc Natl Acad Sci USA, 98 (19), pp. 10966-10971
36. Diniz, B., Pinto, J., Forlenza, O.V., Do CSF total tau, phosphorylated tau, and β-amyloid 42 help to predict progression of mild cognitive impairment to Alzheimer's disease? A systematic review and meta-analysis of the literature (2008) World J Biol Psychiatry, 9 (3), pp. 172-182
37. Diniz, B.S., Nunes, P.V., Yassuda, M.S., Forlenza, O., Diagnosis of mild cognitive impairment revisited after one year. Preliminary results of a prospective study (2009) Dement Geriatr Cogn Disord, 27, pp. 224-231
38. Diniz, B.S., Pinto, J.A., Gonzaga, M.L., Guimarães, F.M., Gattaz, W.F., Forlenza, O.V., To treat or not to treat? A meta-analysis of the use of cholinesterase inhibitors in mild cognitive impairment for delaying progression to Alzheimer's disease (2009) Eur Arch Psychiatry Clin Neurosci, 259, pp. 248-256
39. Diniz, B.S., Teixeira, A.L., Talib, L.L., Mendonça, V.A., Gattaz, W.F., Forlenza, O.V., Serum brain-derived neurotrophic factor level is reduced in antidepressant-free patients with late-life depression (2010) World J Biol Psychiatry, 11 (3), pp. 550-555
40. Drzezga, A., Grimmer, T., Riemenschneider, M., Lautenschlager, N., Siebner, H., Alexopoulus, P., Minoshima, S., Kurz, A., Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET (2005) J Nucl Med, 46 (10), pp. 1625-1632
41. Dubois, B., Feldman, H.H., Jacova, C., Dekosky, S., Barberger-Gateau, P., Cummings, J., Delacourte, A., Jicha, G., Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria (2007) Lancet Neurol, 6, pp. 734-746
42. Edison, P., Archer, H.A., Hinz, R., Hammers, A., Pavese, N., Tai, Y.F., Hotton, G., Brooks, D.J., Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study (2007) Neurology, 68, pp. 501-508
43. Elias, M.F., Beiser, A., Wolf, P.A., Au, R., White, R.F., D'Agostino, R.B., The preclinical phase of alzheimer disease: A 22-year prospective study of the Framingham Cohort (2000) Arch Neurol, 57, pp. 808-813
44. Fagan, A.M., Mintun, M.A., Mach, R.H., Lee, S.Y., Dence, C.S., Shah, A.R., LaRossa, G.N., Holtzman, D.M., Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans (2006) Ann Neurol, 59 (3), pp. 512-519
45. Fagan, A., Roe, C.M., Xiong, C., Mintun, M.A., Morris, J., Holtzman, D., Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults (2007) Arch Neurol, 64, pp. 343-349
46. Fagan, A.M., Mintun, M.A., Shah, A.R., Aldea, P., Roe, C.M., Mach, R.H., Marcus, D., Holtzman, D.M., Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease (2009) EMBO Mol Med, 1 (8-9), pp. 371-380
47. Feldman, H.H., Ferris, S., Winblad, B., Sfikas, N., Mancione, L., He, Y., Tekin, S., del Ser, T., Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study (2007) Lancet Neurol, 6, pp. 501-512
48. Fellgiebel, A., Siessmeier, T., Scheurich, A., Winterer, G., Bartenstein, P., Schmidt, L.G., Möller, M.J., Association of elevated phospho-tau levels with Alzheimer-typical 18F-fluoro-2-deoxy-D-glucose positron emission tomography findings in patients with mild cognitive impairment (2004) BPS, 56, pp. 279-283
49. Ferreira, L.K., Diniz, B.S., Forlenza, O.V., Busatto, G.F., Zanetti, M.V., Neurostructural predictors of Alzheimer's disease: A meta-analysis of VBM studies (2001) Neurobiol Aging, , [epub ahead of print]
50. Fischer, P., Jungwirth, S., Zehetmayer, S., Weiss-gram, S., Hoenigschnabl, S., Gelpi, E., Krampla, W., Tragl, K.H., Conversion of subtypes of mild cognitive impairment to Alzheimer dementia (2007) Neurology, 68, pp. 288-291
51. Fjell, A.M., Walhovd, K.B., Fennema-Notestine, C., McEvoy, L.K., Hagler, D.J., Holland, D., Blennow, K., Dale, A.M., Alzheimer's Disease Neuroimaging Initiative. Brain atrophy in healthy aging is related to CSF levels of Aβ1-42 (2010) Cereb Cortex, 20 (9), pp. 2069-2079
52. Forlenza, O.V., Chiu, E., Mild cognitive impairment: a concept ready to move on? (2008) Cur Opin Psychiatry, 21, pp. 529-532
53. Forlenza, O.V., Diniz, B.S., Nunes, P.V., Memoria, C.M., Yassuda, M.S., Gattaz, W.F., Diagnostic transitions in mild cognitive impairment subtypes (2009) Int Psychogeriatr, 21 (6), pp. 1088-1095
54. Forlenza, O.V., Diniz, B.S., Talib, L.L., Mendonca, V.A., Ojopi, E.B., Gattaz, W.F., Teixeira, A.L., Increased serum IL-1beta level in Alzheimer's disease and mild cognitive impairment (2009) Dement Geriatr Cogn Disord, 28 (6), pp. 507-512
55. Forlenza, O.V., Diniz, B.S., Talib, L.L., Radanovic, M., Yassuda, M.S., Ojopi, E.B., Gattaz, W.F., Clinical and biological predictors of Alzheimer's disease in patients with amnestic mild cognitive impairment (2010) Rev Bras Psiquiatr, 32 (3), pp. 216-222
56. Forlenza, O.V., Diniz, B.S., Teixeira, A.L., Ojopi, E.B., Talib, L.L., Mendonca, V.A., Izzo, G., Gattaz, W.F., Effect of brain-derived neurotrophic factor Val66Met polymorphism and serum levels on the progression of mild cognitive impairment (2010) World J Biol Psychiatry, 11 (6), pp. 774-780
57. Forlenza, O.V., Torres, C.A., Talib, L.L., de Paula, V.R., Joaquim, H.G., Diniz, B.S., Gattaz, B.S., Increased platelet GSK3B activity in patients with mild cognitive impairment and Alzheimer's disease (2010) J Psychiatr Res, 45 (2), pp. 220-224
58. Forlenza, O.V., Diniz, B.S., Radanovic, M., Santos, F.S., Talib, L.L., Gattaz, W.F., Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial (2011) Br J Psychiatry, 198 (5), pp. 351-356
59. Forsberg, A., Engler, H., Almkvist, O., Blomquist, G., Hagman, G., Wall, A., Ringheim, A., Nordberg, A., PET imaging of amyloid deposition in patients with mild cognitive impairment (2008) Neurobiol Aging, 29, pp. 1456-1465
60. Frank, R.A., Galasko, D., Hampel, H., Hardy, J., de Leon, M.J., Mehta, P.D., Rogers, J., Trojanowski, J.Q., National Institute on Aging Biological Markers Working G. Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group
61. NIA initiative on neuroimaging in Alzheimer's disease (2003) Neurobiol Aging, 24, pp. 521-536
62. Gomez-Isla, T., Blesa, R., Boada, M., Clarimen, J., del Ser, T., Domenech, G., Ferro, J.M., Martinez-Lage, J.M., A randomized, double-blind, placebo controlled-trial of triflusal in mild cognitive impairment: the TRIMCI study (2008) Alzheimer Dis Assoc Disord, 22, pp. 21-29
63. Graff-Radford, N.R., Crook, J.E., Lucas, J., Boeve, B.F., Knopman, D.S., Ivnik, R.J., Smith, G.E., Younkin, S.G., Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease (2007) Arch Neurol, 64 (3), pp. 354-362
64. Grassi-Oliveira, R., Stein, L.M., Lopes, R.P., Teixeira, A.L., Bauer, M.E., Low plasma brain-derived neurotrophic factor and childhood physical neglect are associated with verbal memory impairment in major depression--a preliminary report (2008) Biol Psychiatry, 64, pp. 281-285
65. Grassi-Oliveira, R., Brietzke, E., Pezzi, J., Lopes, R., Teixeira, A., Bauer, M., Increased soluble tumor necrosis factor-alpha receptors in patients with major depressive disorder (2009) Psychiatry Clin Neurosci, 63, pp. 202-208. , 19175760
66. Hämäläinen, A., Tervo, S., Grau-Olivares, M., Niskanen, E., Pennanen, C., Huuskonen, J., Kivipelto, M., Vanhanen, M., Voxel-based morphometry to detect brain atrophy in progressive mild cognitive impairment (2007) NeuroImage, 37, pp. 1122-1131
67. Hampel, H., Teipel, S.J., Fuchsberger, T., Andreasen, N., Wiltfang, J., Otto, M., Shen, Y., Farlow, M., Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment (2004) Mol Psychiatry, 9, pp. 705-710
68. Hansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., Minthon, L., Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study (2006) Lancet Neurol, 5 (3), pp. 228-234
69. Hansson, O., Buchhave, P., Zetterberg, H., Blennow, K., Minthon, L., Warkentin, S., Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer's disease (2009) Neurobiol Aging, 30, pp. 165-173
70. Hansson, O., Zetterberg, H., Vanmechelen, E., Vanderstichele, H., Andreasson, U., Londos, E., Wallin, A., Blennow, K., Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment (2010) Neurobiol Aging, 31 (3), pp. 357-367
71. Hashimoto, R., Hirata, Y., Asada, T., Yamashita, F., Nemoto, K., Mori, T., Moriguchi, Y., Ohnishi, T., Effect of the brain-derived neurotrophic factor and the apolipoprotein E polymorphisms on disease progression in preclinical Alzheimer's disease (2009) Genes Brain Behav, 8 (1), pp. 43-52
72. Herholz, K., Salmon, E., Perani, D., Baron, J.C., Holthoff, V., Frölich, L., Schönknecht, P., Heiss, W.D., Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET (2002) Neuroimage, 17 (1), pp. 302-316
73. Holmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A., Jones, R.W., Neal, J.W., Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial (2008) Lancet, 372, pp. 216-223
74. Hooper, C., Killick, R., Lovestone, S., The GSK3 hypothesis of Alzheimer's disease (2008) J Neurochem, 104, pp. 1433-1439
75. Hye, A., Kerr, F., Archer, N., Foy, C., Poppe, M., Brown, R., Hamilton, G., Lovestone, S., Glycogen synthase kinase-3 is increased in white cells early in Alzheimer's disease (2005) Neurosci Lett, 373, pp. 1-4
76. Jack, C., Lowe, V., Weigand, S., Wiste, H., Senjem, M., Knopman, D., Shiung, M., Kemp, B., Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease (2009) Brain, 132 (5), pp. 1355-1365
77. Jack, C.R., Knopman, D.S., Jagust, W.J., Shaw, L.M., Aisen, P.S., Weiner, M.W., Petersen, R.C., Trojanowski, J.Q., Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade (2010) Lancet Neurol, 9 (1), pp. 119-128
78. Jefferson, A.L., Byerly, L.K., Vanderhill, S., Lambe, S., Wong, S., Ozonoff, A., Karlawish, J.H., Characterization of activities of daily living in individuals with mild cognitive impairment (2008) Am J Geriatr Psychiatry, 16 (5), pp. 375-383
79. Josephs, K.A., Whitwell, J.L., Ahmed, Z., Shiung, M.M., Weigand, S.D., Knopman, D.S., Boeve, B.F., Jack Jr., C.R., Beta-amyloid burden is not associated with rates of brain atrophy (2008) Ann Neurol, 63 (2), pp. 204-212
80. Jorm, A.F., Assessment of cognitive impairment and dementia using informant report (1996) Clin Psychol Rev, 16, pp. 51-73
81. Jovicich, J., Czanner, S., Han, X., Salat, D., van der Kouwe, A., Quinn, B., Pacheco, J., Fischl, B., MRI-derived measurements of human subcortical, ventricular and intracranial brain volumes. Reliability effects of scan sessions, acquisition sequences, data analyses, scanner upgrade, scanner vendors and field strengths (2009) Neuroimage, 46 (1), pp. 177-192
82. Kemppainen, N.M., Aalto, S., Wilson, I.A., Nagren, K., Helin, S., Brack, A., Oikonen, V., Viitanen, M., PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment (2007) Neurology, 68, pp. 1603-1606
83. Kim, K.R., Lee, K.S., Cheong, H.K., Eom, J.S., Oh, B.H., Hong, C.H., Characteristic profiles of instrumental activities of daily living in different subtypes of mild cognitive impairment (2009) Dement Geriatr Cogn Disord, 27 (3), pp. 278-285
84. Klunk, W., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D.P., Bergström, M., Estrada, S., Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B (2004) Ann Neurol, 55, pp. 306-319
85. Lewczuk, P., Beck, G., Ganslandt, O., Esselmann, H., Deisenhammer, F., Regeniter, A., Petereit, H.F., Oschmann, P., International quality control survey of neurochemical dementia diagnostics (2006) Neurosci Lett, 409, pp. 1-4
86. Loewenstein, D.A., Acevedo, A., Agron, J., Duara, R., Stability of neurocognitive impairment in different subtypes of mild cognitive impairment (2007) Dement Geriatr Cogn Disord, 23, pp. 82-86
87. Lopez, O.L., Kuller, L.H., Mehta, P.D., Becker, J.T., Gach, H.M., Sweet, R.A., Chang, Y.F., DeKosky, S.T., Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study (2008) Neurology, 70 (19), pp. 1664-1671
88. Maruyama, M., Arai, H., Sugita, M., Tanji, H., Higuchi, M., Okamura, N., Matsui, T., Yoshida, H., Cerebrospinal fluid amyloid beta(1-42) levels in the mild cognitive impairment stage of Alzheimer's disease (2001) Exp Neurol, 172, pp. 433-436
89. Mathis, C., Wang, Y., Holt, D.P., Huang, G.F., Debnath, M.L., Klunk, W., Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents (2003) J Med Chem, 46, pp. 2740-2754
90. Mattson, M.P., Pathways towards and away from Alzheimer's disease (2004) Nature, 430, pp. 631-639
91. Mattsson, N., Zetterberg, H., Hansson, O., Andreasen, N., Parnetti, L., Jonsson, M., Herukka, S.K., Ewers, M., CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment (2009) JAMA, 302, pp. 385-393
92. Mattsson, N., Blennow, K., Zetterberg, H., Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer's disease: united we stand, divided we fall (2010) Clin Chem lab Med, 48, pp. 603-607
93. McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., Stadlan, E.M., Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease (1984) Neurology, 34 (7), pp. 939-944
94. Mielke, R., Pietrzyk, U., Jacobs, A., Fink, G.R., Ichimiya, A., Kessler, J., Herholz, K., Heiss, W.D., HMPAO SPET and FDG PET in Alzheimer's disease and vascular dementia: comparison of perfusion and metabolic pattern (1994) Eur J Nucl Med, 21 (10), pp. 1052-1060
95. Mitchell, A., Shiri-Feshki, M., Rate of progression of mild cognitive impairment to dementia - meta-analysis of 41 robust inception cohort studies (2009) Acta Psychiatr Scand, 119 (4), pp. 252-265
96. Morris, J.C., Roe, C.M., Grant, E.A., Head, D., Storandt, M., Goate, A.M., Fagan, A.M., Mintun, M.A., Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease (2009) Arch Neurol, 66 (12), pp. 1469-1475
97. Mosconi, L., Perani, D., Sorbi, S., Herholz, K., Nacmias, B., Holthoff, V., Salmon, E., Pupi, A., MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET (2004) Neurology, 63 (12), pp. 2332-2340
98. Mosconi, L., Tsui, W.H., Herholz, K., Pupi, A., Drzezga, A., Lucignani, G., Reiman, E.M., de Leon, M.J., Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias (2008) J Nucl Med, 49 (3), pp. 390-398
99. Mrak, R.E., Neuropathology and the Neuroinflammation Idea (2009) J Alzheimer Dis, 18 (3), pp. 473-481
100. Nobili, F., Salmaso, D., Morbelli, S., Girtler, N., Piccardo, A., Brugnolo, A., Dessi, B., Pagani, M., Principal component analysis of FDG PET in amnestic MCI (2008) Eur J Nucl Med Mol Imaging, 35 (12), pp. 2191-2202
101. Nordlund, A., Rolstad, S., Klang, O., Lind, K., Pedersen, M., Blennow, K., Edman, A., Wallin, A., Episodic memory and speed/attention deficits are associated with Alzheimer-typical CSF abnormalities in MCI (2008) JINS, 14, pp. 582-590
102. Okello, A., Koivunen, J., Edison, P., Archer, H.A., Turkheimer, F.E., Nagren, K., Bullock, R., Brooks, D.J., Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study (2009) Neurology, 73, pp. 754-760
103. Padovani, A., Borroni, B., Colciaghi, F., Abnormalities in the pattern of platelet amyloid precursor protein forms in patients with mild cognitive impairment and Alzheimer disease (2002) Arch Neurol, 59, pp. 71-75
104. Padovani, A., Pastorino, L., Borroni, B., Pettenati, C., Cottini, E., Agosti, C., Lenzi, G.L., Di Luca, M., Amyloid precursor protein in platelets: a peripheral marker for the diagnosis of sporadic AD (2001) Neurology, 57, pp. 2243-2248
105. Palmer, K., Wang, H.X., Bäckman, L., Winblad, B., Fratiglioni, L., Differential evolution of cognitive impairment in nondemented older persons: results from the Kungsholmen Project (2002) Am J Psychiatry, 159, pp. 436-442
106. Parnetti, L., Lanari, A., Saggese, E., Spaccatini, C., Gallai, V., Cerebrospinal fluid biochemical markers in early detection and in differential diagnosis of dementia disorders in routine clinical practice (2003) Neurol Sci, 24, pp. 199-200
107. Parnetti, L., Lanari, A., Silvestrelli, G., Saggese, E., Reboldi, P., Diagnosing prodromal Alzheimer's disease: role of CSF biochemical markers (2006) Mech Ageing Dev, 127, pp. 129-132
108. Parra, M.A., Abrahams, S., Fabi, K., Logie, R., Luzzi, S., Della Sala, S., Short term memory binding deficits in Alzheimer's Disease (2009) Brain, 132, pp. 1057-1066
109. Peng, S., Garzon, D.J., Marchese, M., Klein, W., Ginsberg, S.D., Francis, B.M., Mount, H.T., Fahnestock, M., Decreased brain-derived neurotrophic factor depends on amyloid aggregation state in transgenic mouse models of Alzheimer's disease (2009) J Neurosci, 29, pp. 9321-9329
110. Peng, S., Wuu, J., Mufson, E.J., Fahnestock, M., Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer's disease (2005) J Neurochem, 93, pp. 1412-1421
111. Pereira, F.S., Oliveira, A.M., Diniz, B.S., Forlenza, O.V., Yassuda, M.S., Cross-cultural adaptation, reliability and validity of the DAFS-R in a sample of Brazilian older adults (2010) Arch Clin Neuropsychol, 25, pp. 335-343
112. Pereira, F.S., Yassuda, M.S., Oliveira, A.M., Diniz, B.S., Radanovic, M., Talib, L.L., Gattaz, W.F., Forlenza, O.V., Profiles of functional deficits in mild cognitive impairment and dementia: benefits from objective measurement (2010) J Int Neuropsychol Soc, 16, pp. 297-305
113. Pereira, F.S., Yassuda, M.S., Oliveira, A.M., Forlenza, O.V., Executive dysfunction correlates with impaired functional status in older adults with varying degrees of cognitive impairment (2008) Int Psychogeriatr, 20, pp. 1104-1115
114. Peres, K., Helmer, C., Amieva, H., Orgogozo, J., Rouch, I., Dartigues, J., Barberger-Gateau, P., Natural History of Decline in Instrumental Activities of Daily Living Performance over the 10 Years Preceding the Clinical Diagnosis of Dementia: A Prospective Population-Based Study (2008) J Am Geriatr Soc, 56 (1), pp. 37-44
115. Petersen, R.C., Smith, G.E., Waring, S.C., Ivnik, R.J., Tangalos, E.G., Kokmen, E., Mild cognitive impairment: clinical characterization and outcome (1999) Arch Neurol, 56 (3), pp. 303-308
116. Petersen, R.C., Stevens, J.C., Ganguli, M., Tangalos, E.G., Cummings, J.L., DeKosky, S.T., Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology (2001) Neurology, 56, pp. 1133-1142
117. Petersen, R.C., Mild cognitive impairment as a diagnostic entity (2004) J Intern Med, 256, pp. 183-194
118. Petersen, R.C., Thomas, R.G., Grundman, M., Bennett, D., Doody, R., Ferris, S., Galasko, D., Levey, A., Vitamin E and donepezil for the treatment of mild cognitive impairment (2005) New Engl J Med, 352, pp. 2379-2388
119. Petersen, R.C., Knopman, D.S., MCI is a clinically useful concept (2006) Int Psychogeriatr, 18, pp. 314-394
120. Petrie, E.C., Cross, D.J., Galasko, D., Schellenberg, G.D., Raskind, M.A., Peskind, E.R., Minoshima, S., Preclinical evidence of Alzheimer changes: convergent cerebrospinal fluid biomarker and fluorodeoxyglucose positron emission tomography findings (2009) Arch Neurol, 66, pp. 632-637
121. Reiber, H., Dynamics of brain-derived proteins in cerebrospinal fluid (2001) Clin Chim Acta, pp. 310173-310186
122. Reiman, E.M., Chen, K., Liu, X., Bandy, D., Yu, M., Lee, W., Ayutyanont, N., Langbaum, J.B., Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease (2009) Proc Natl Acad Sci USA, 106, pp. 6820-6825
123. Resnick, S.M., Sojkova, J., Zhou, Y., An, Y., Ye, W., Holt, D.P., Dannals, R.F., Ferrucci, L., Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB (2010) Neurology, 74, pp. 807-815
124. Riemenschneider, M., Lautenschlager, N., Wagenpfeil, S., Diehl, J., Drzezga, A., Kurz, A., Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment (2002) Arch Neurol, 59, pp. 1729-1734
125. Ridha, B.H., Barnes, J., Bartlett, J.W., Godbolt, A., Pepple, T., Rossor, M.N., Fox, N.C., Tracking atrophy progression in familial Alzheimer's disease: a serial MRI study (2006) Lancet Neurol, 5 (10), pp. 828-834
126. Rowe, C.C., Ackerman, U., Browne, W., Mulligan, R., Pike, K.L., O'Keefe, G., Tochon-Danguy, H., Jones, G., Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism (2008) Lancet Neurol, 7, pp. 129-135
127. Rozzini, L., Chilovi, B.V., Conti, M., Bertoletti, E., Delrio, I., Trabucchi, M., Padovani, A., Conversion of amnestic Mild Cognitive Impairment to dementia of Alzheimer type is independent to memory deterioration (2007) Int J Geriatr Psychiatry, 22, pp. 1217-1222
128. Salloway, S., Sperling, R., Gilman, S., Fox, N.C., Blennow, K., Raskind, M., Sabbagh, M., van Dyck, C.H., A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease (2009) Neurology, 73, pp. 2061-2070
129. Scalzo, P., Kümmer, A., Bretas, T.L., Cardoso, F., Teixeira, A.L., Serum levels of brain-derived neurotrophic factor correlate with motor impairment in Parkinson's disease (2010) J Neurol, 257 (4), pp. 540-545
130. Seo, S.W., Im, K., Lee, J.M., Kim, Y.H., Kim, S.T., Kim, S.Y., Yang, D.W., Na, D.L., Cortical thickness in single- versus multiple-domain amnestic mild cognitive impairment (2007) NeuroImage, 36, pp. 289-297
131. Shaw, L., Vanderstichele, H., Knapik-Czajka, M., Clark, C., Aisen, P., Petersen, R., Blennow, K., Lewczuk, P., Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects (2009) Ann Neurol, 65 (4), pp. 403-413
132. Singh, V., Chertkow, H., Lerch, J.P., Evans, A.C., Dorr, A.E., Kabani, N.J., Spatial patterns of cortical thinning in mild cognitive impairment and Alzheimer's disease (2006) Brain, 129, pp. 2885-2893
133. Small, B.J., Fratiglioni, L., Viitanen, M., Winblad, B., Bäckman, L., The course of cognitive impairment in preclinical Alzheimer disease: three- and 6-year follow-up of a population-based sample (2000) Arch Neurol, 57, pp. 839-844
134. Small, G.W., Kepe, V., Ercoli, L.M., Siddarth, P., Bookheimer, S.Y., Miller, K.J., Lavretsky, H., Vinters, H., PET of brain amyloid and tau in mild cognitive impairment (2006) New Engl J Med, 355, pp. 2652-2663
135. Stephan, B.C., Matthews, F.E., McKeith, I.G., Bond, J., Brayne, C., Medical Research Council Cognitive Function and Aging Study. Early cognitive change in the general population: how do different definitions work? (2007) J Am Geriatr Soc, 55 (10), pp. 1534-1540
136. Stomrud, E., Hansson, O., Blennow, K., Minthon, L., Londos, E., Cerebrospinal fluid biomarkers predict decline in subjective cognitive function over 3 years in healthy elderly (2007) Dement Geriatr Cogn Disord, 24 (2), pp. 118-124
137. Sundelöf, J., Giedraitis, V., Irizarry, M.C., Sundström, J., Ingelsson, E., Rönnemaa, E., Arnlöv, J., Basun, H., Plasma beta amyloid and the risk of Alzheimer disease and dementia in elderly men: a prospective, population-based cohort study (2008) Arch Neurol, 65, pp. 256-263
138. Sunderland, T., Linker, G., Mirza, N., Putnam, K.T., Friedman, D.L., Kimmel, L.H., Bergeson, J., Cohen, R.M., Decreased beta-amyloid1 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease (2003) JAMA, 289 (16), pp. 2094-2103
139. Swerdlow, R.H., Is aging part of Alzheimer's disease, or is Alzheimer's disease part of aging? (2007) Neurobiol Aging, 28, pp. 1465-1480
140. Swerdlow, R.H., Khan, S.M., The Alzheimer's disease mitochondrial cascade hypothesis: an update (2009) Exp Neurol, 218, pp. 308-315
141. Tabert, M.H., Albert, S.M., Borukhova-Milov, L., Camacho, Y., Pelton, G., Liu, X., Stern, Y., Devanand, D.P., Functional deficits in patients with mild cognitive impairment: prediction of AD (2002) Neurology, 58, pp. 758-764
142. Tan, Z.S., Beiser, A.S., Vasan, R.S., Roubenoff, R., Dinarello, C.A., Harris, T.B., Benjamin, E.J., Wolf, P.A., Inflammatory markers and the risk of Alzheimer disease: the Framingham Study (2007) Neurology, 68, pp. 1902-1908
143. Tang, K., Hynan, L.S., Baskin, F., Rosenberg, R.N., Platelet amyloid precursor protein processing: a bio-marker for Alzheimer's disease (2006) J Neurol Sci, 240, pp. 53-58
144. Tapia-Arancibia, L., Aliaga, E., Silhol, M., Arancibia, S., New insights into b